Refine by
Clinical Development Articles & Analysis
68 articles found
For centuries outbreaks of numerous diseases called pandemics would plague human populations in large regions or even world-wide. Throughout history there have been a number of widespread pandemics the most devastating being the Black Death pandemic that killed over 75 million people in the 1350’s and the latest being influenza outbreaks, also known as the Spanish flu, in 1918 and ...
Preclinical drug discovery represents a critical phase in the development of new therapeutics. It is the process that bridges the gap between basic research and clinical testing, allowing for the evaluation of potential drug candidates in biological systems before they are tested in humans. ...
One of the primary uses is in drug testing and development. Researchers utilize these cell lines to screen potential therapeutic agents, examining their effectiveness in inhibiting cancer cell growth. This screening process helps identify promising candidates for further development into clinical treatments. In addition to drug testing, ...
Recombinant protein drugs refer to protein products that originate from animals and plants and are developed through biotechnology research. These protein drugs exhibit certain biological activity and can prevent, diagnose, and treat diseases in humans, animals, and plants. ...
Currently, there are more than 160 PROTAC projects under development worldwide, of which nearly 20 projects are in clinical development. ...
Medical advancement relies on clinical trials, which are essential for the development of safe and effective innovative treatments. ...
They have the advantages of small size, high stability, and good penetration, and therefore have a wide range of application prospects in the fields of clinical treatment, diagnostic reagent development, etc.Characteristics of NanobodiesThe size of nanobodies usually ranges between 10-15kDa, which is only 1/10 of the size of regular antibodies. ...
Dr. Kate Sasser from Tempus led a discussion on the potential of antibody-drug conjugates (ADCs), their challenges in targeting tumor antigens, and the future of cancer treatment with Dr. Daniel Johnson, Dr. Funda Meric-Bernstam, and Dr. Kellogg Parsons. The oncology field is rapidly advancing with the development of antibody-drug conjugates (ADCs), offering new hope for ...
ByTempus
Currently, RDC drugs have made significant breakthroughs in cancer treatment alongside the development of antibody drugs and ADCs. Antibodies are relatively effective for hematologic malignancies. ...
As immune checkpoint tracers for macrophage-infiltrating immune diseases, nanobodies can identify immune response patterns, predict treatment responses, and track the biological processes of immune system activation, thereby improving the effectiveness of immunotherapy. The clinical research targets of nanobodies used for molecular diagnosis include HER2, HER3, PD-L1, AlbudAb, ...
Therefore, there is a need to deepen our understanding of the physical, chemical, and biological properties of these adjuvants to provide a theoretical basis for determining the quality attributes of each adjuvant and selecting the appropriate type of adjuvant as early as possible in the clinical development phase. Type of Aluminum Adjuvants The two main types of ...
Maternal serum samples were collected between 20 and 37 weeks of gestation. Clinical suspicion of preeclampsia was defined as presence of new-onset proteinuria, or clinical symptoms of preeclampsia. Subjects with a clinical diagnosis of preeclampsia at the time of enrollment were excluded. ...
The opioid crisis in the United States is a devastating public health issue, with over 70,000 overdose deaths annually, largely driven by the highly potent synthetic opioid fentanyl. The urgency to address this crisis has spurred the development of innovative therapies to prevent and reverse fentanyl overdoses. In this blog, we will explore the groundbreaking preclinical work on CSX-1004, a fully ...
With the rapid development of antibody-drug conjugate (ADC), more and more companies have entered the field of ADC research and development, and various types of ADC technologies and branches have emerged. ...
In the clinical development phase, single-cell RNA sequencing has the potential to inform decision-making in several ways. ...
Nearly 100 recombinant vaccine candidates are currently in Phase I clinical development, currently the largest number of all types. The success of COVID-19 mRNA vaccines has laid the foundation for the development of nucleic acid vaccines, including mRNA and DNA vaccines. ...
Relevance of scRNA-seq in Drug Development In drug development, scRNA-seq plays a crucial role in selecting relevant preclinical disease models. ...
Patricia A. Pellikka from Mayo Clinic will share some of the evidence around EchoGo® Heart Failure, including her research with Ultromics and her involvement in the development of their AI algorithm. ...
After more than 20 years of development, ADC biopharmaceuticals are becoming the main force in the treatment of cancer. ...
Preliminary results of a large-scale study demonstrating the clinical benefits of EchoGo® Heart Failure were shared at the American College of Cardiology (ACC 2023) conference last month. ...